[HTML] sciencedirect.com

[HTML][HTML] Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer …

N Yamamoto, T Seto, M Nishio, K Goto, I Okamoto… - Lung Cancer, 2021 - Elsevier
Abstract Objectives The JO25567 randomized Phase II study demonstrated a statistically
significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared …
被引用次数：86 相关文章

Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival …

N Yamamoto, T Seto, M Nishio, K Goto… - Lung …, 2021 - lungcancerjournal.info
Abstract Objectives The JO25567 randomized Phase II study demonstrated a statistically
significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared …

[引用][C] Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer …

N Yamamoto, T Seto, M Nishio, K Goto, I Okamoto… - Lung Cancer, 2021 - cir.nii.ac.jp
Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR
mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the …

Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival …

N Yamamoto, T Seto, M Nishio… - Lung cancer …, 2021 - pubmed.ncbi.nlm.nih.gov
Objectives The JO25567 randomized Phase II study demonstrated a statistically significant
progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared with …

Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival …

N Yamamoto, T Seto, M Nishio, K Goto… - Lung …, 2021 - kyushu-u.elsevierpure.com
Objectives: The JO25567 randomized Phase II study demonstrated a statistically significant
progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared with …

Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival …

N Yamamoto, T Seto, M Nishio, K Goto… - Lung Cancer …, 2020 - europepmc.org
Objectives The JO25567 randomized Phase II study demonstrated a statistically significant
progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared with …